Matthew Wood is Professor of Neuroscience and Deputy Head of the Medical Sciences Division at the University of Oxford. He directs the Laboratory of RNA biology and Neuromuscular Disease investigating development of RNA-based medicines for neuromuscular disease focusing on the development of advanced generation antisense oligonucleotides for Duchenne muscular dystrophy and related neuromuscular conditions.

He has pioneered the development of novel delivery systems including peptide and exosome-based technologies for the targeted delivery of macromolecular biologics, including oligonucleotides, to tissues including the brain. He is the founder of the biotech spin-outs Evox Therapeutics (developing therapeutic exosome technology) and PepGen (developing peptide based drug delivery technology), is an advisor to numerous research funding agencies including the UK Medical Research Council and is a director of the University of Oxford’s technology transfer organization, Oxford University Innovation.